CLAIMS

1. A compound of formula (I):



(I)

wherein:

A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;

B represents a phenyl or pyridyl ring;

Z represents O, S, SO, or SO_2;

R^1 represents CO_2H, CN, $CONR^5R^6$, CH_2CO_2H, optionally substituted SO_2alkyl, $SO_2NR^5R^6$, $NR^5CONR^5R^6$, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;

R^{2a} and R^{2b} each independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO_2alkyl, SR^5, NO_2, optionally substituted aryl, $CONR^5R^6$ or optionally substituted heteroaryl;

R^x represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally substituted by a group independently selected from NR^4, O and SO_n, wherein n is 0, 1 or 2, optionally substituted alkenyl or optionally substituted alkynyl: or R^x represents optionally substituted CQ^aQ^bheterocyclyl, optionally substituted CQ^aQ^b-bicyclic heterocyclyl or optionally substituted CQ^aQ^b-aryl;

R^4 represents hydrogen or an optionally substituted alkyl;

R^5 represents hydrogen or an optionally substituted alkyl;

R^6 represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO_2aryl, optionally substituted SO_2alkyl, optionally substituted SO_2heteroaryl, CN, optionally substituted CQ^aQ^baryl, optionally substituted CQ^aQ^bheteroaryl or COR^7;

R^7 represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

R^8 and R^9 each independently represents hydrogen, chloro, fluoro, CF_3, C_{1-3}alkoxy or C_{1-3}alkyl;

Q^a and Q^b each independently selected from hydrogen and CH_3; and

when A is a 6-membered ring the R^1 substituent and cyclohexene ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring

or bicyclic heterocyclyl group the R^1 substituent and cyclohexene ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other,
or a derivatives thereof.

2. A compound according to claim 1 wherein A is pyridyl.

3. A compound according to claim 1 or claim 2 wherein R^1 represents CO_2H.

4. A compound selected from:

6-[2-(5-chloro-2-{[(4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-{2-[2-{[(4-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-{[(2,4-difluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-[2-(5-(trifluoromethyl)-2-{[(2,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-{2-[2-{[(4-chloro-2-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-[2-(5-(trifluoromethyl)-2-{[(2,4,6-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-{2-[2-{[(2-chlorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-{[(3,4-difluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-{[(2-chloro-4-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-{[(4-chlorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-{[(2-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
6-{2-[2-[(phenylmethyl)oxy]-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-2-pyridinecarboxylic acid;
5-{2-[2-{[(2-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;
5-{2-[2-{[(2,4-difluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;

5-[2-(5-(trifluoromethyl)-2-{[(2,4,6-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-{2-[2-{[(4-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;
5-[2-(5-(trifluoromethyl)-2-{[(2,3,4-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-(trifluoromethyl)-2-{[(2,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-{2-[2-{[(2-chloro-4-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;
5-{2-[2-{[(4-chloro-2-fluorophenyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;
5-{2-[2-[(phenylmethyl)oxy]-5-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl}-3-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2,4,6-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(2-chloro-4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(3,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(3,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-chloro-2-{[(4-chlorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
5-(2-{5-chloro-2-[(phenylmethyl)oxy]phenyl}-1-cyclohexen-1-yl)-3-pyridinecarboxylate
5-[2-(5-chloro-2-{[(2-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-chloro-2-{[(4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-chloro-2-{[(2,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-chloro-2-{[(2,3,4-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;
5-[2-(5-chloro-2-{[(2-chloro-4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-3-pyridinecarboxylic acid;

6-(2-{5-bromo-2-[(phenylmethyl)oxy]phenyl}-1-cyclohexen-1-yl)-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(3,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2,3,4-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2,4,5-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2,4,6-trifluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;
6-[2-(5-bromo-2-{[(2-chloro-4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid; and
3-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid;

and derivatives thereof.

5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.

6. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.

7. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE_2 at EP_1 receptors.

8. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE_2 at EP_1 receptors which comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof.

9. A method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof.

10. A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof.

11. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE_2 at EP_1 receptors.

12. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

13. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.